Document:

<PAGE>

                                                               EXHIBIT 10.13 (a)

          FIRST AMENDMENT TO OCCIDENTAL ASSET CONTRIBUTION AGREEMENT
          ----------------------------------------------------------

     This First Amendment to Occidental Asset Contribution Agreement (this
"First Amendment"), dated as of September 30, 2001, is entered into by and among
Occidental Petrochem Partner 1, Inc., a Delaware corporation, Occidental
Petrochem Partner 2, Inc., a Delaware corporation, PDG Chemical Inc., a Delaware
corporation, Occidental Petrochem Partner GP, Inc., a Delaware corporation ("New
GP"; collectively, with the other preceding entities the "Oxy Partners"), and
Equistar Chemicals, LP, a Delaware limited partnership (the "Partnership").

                                   RECITALS:
                                   --------

     A.  Certain of the Oxy Partners and the Partnership were among the parties
to that certain Agreement and Plan of Merger and Asset Contribution, dated as of
May 15, 1998, (the "Asset Contribution Agreement"), together with Oxy
Petrochemicals Inc., a Delaware corporation ("OPI"), also an affiliate of
Occidental Petroleum Corporation ("Occidental").  Pursuant to the terms of the
Asset Contribution Agreement, OPI merged into the Partnership on the Closing
Date and ceased to exist thereafter.

     B.  Concurrently with the execution and delivery of the Asset Contribution
Agreement, certain affiliates of Occidental, Lyondell Chemical Company
("Lyondell") and Millennium Petrochemicals Inc. ("Millennium") entered into that
certain Amended and Restated Partnership Agreement of Equistar Chemicals, LP
dated May 15, 1998 (the "Partnership Agreement").  Subsequently, the partners of
the Partnership agreed to enter into that certain First Amendment to Amended and
Restated Limited Partnership Agreement of Equistar Chemicals, LP, dated as of
June 30, 1998 (the "Amendment"), to the Partnership Agreement.  Pursuant to the
Amendment, Occidental effected a reorganization of its interests in the
Partnership, including, among other things, a transfer of the remaining GP
interest of PDG to New GP, which is a successor to PDG and any interest of PDG
in and to the Partnership.

     C.  Recently, the Oxy Partners and the Partnership (collectively, the
"Parties" and each individually, a "Party") have agreed to certain amendments
clarifying the treatment of, and procedures pertaining to the management of,
certain claims that may arise under the Asset Contribution Agreement.
Simultaneously, and as an integral part of the resolution of the matters
referenced herein, (i) the Partnership and certain affiliates of Millennium have
agreed to settle certain claims and make certain amendments pursuant to that
certain Second Amendment to Millennium Asset Contribution Agreement dated as of
September 30, 2001 (the "Millennium Second Amendment") and (ii) the Partnership
and certain affiliates of Lyondell have agreed to settle certain claims and make
certain amendments pursuant to that certain Second Amendment to Lyondell Asset
Contribution Agreement dated as of September 30, 2001 (the "Lyondell Second
Amendment").

     D.  Accordingly, the Parties desire to amend the Asset Contribution
Agreement on the terms set forth herein.  Capitalized terms used and not
otherwise defined herein shall have the

                                       1
<PAGE>

meanings given such terms in the Asset Contribution Agreement. All section
references in this First Amendment are intended to refer to provisions contained
in the Asset Contribution Agreement.

     NOW THEREFORE, in consideration of the premises and of the mutual covenants
of the Parties hereto, it is hereby agreed  that the Asset Contribution
Agreement is hereby amended as follows:

     Section 1.     Assumption of Liabilities.
                    -------------------------

     (a)  Section 2.5(a)(vi) is hereby amended and restated as follows:

          (vi)      Third Party Claims (including De Minimis Claims) that are
     related to Pre-Closing Contingent Liabilities and that are first asserted
     seven years or more after the Closing Date.

     (b)  The word "and" is hereby deleted from the end of Section 2.5(a)(x) and
added to the end of Section 2.5(a)(xi).

     (c)  A new Section 2.5(a)(xii) is hereby added as follows:

          (xii)     Pre-Closing Contingent Liabilities that do not involve a
     Third Party Claim and De Minimis Claims first asserted against the
     Partnership (and not the Contributor) within seven years after the Closing
     Date.

     Section 2.     Excluded Liabilities.  Section 2.6(i) is hereby amended and
                    --------------------
restated as follows:

          (i)       Any Pre-Closing Contingent Liability that is not an Assumed
     Liability, including any De Minimis Claim that is first asserted against
     Contributor and the Partnership, jointly, within seven years after the
     Closing Date.

     Section 3.     Lowest Cost Response.  The definition of "Lowest Cost
                    --------------------
Response" is hereby amended to delete the phrase "Chemical Substances" in the
first sentence and replace it with the word "condition."

     Section 4.     Effectiveness of this First Amendment.  This First Amendment
                    -------------------------------------
shall be effective from and after the date hereof, except as expressly provided
with respect to certain disputes described in the Millennium Second Amendment;
provided, however, that the execution and delivery of the Millennium Second
Amendment and the Lyondell Second Amendment shall be conditions to the
effectiveness of this First Amendment.  Except as expressly amended by this
First Amendment, all of the terms and provisions of the Asset Contribution
Agreement shall remain in full force and effect among the Parties from and after
the date hereof.

                                       2
<PAGE>

     Section 5.  Counterparts.  This First Amendment may be executed in any
                 ------------
number of counterparts, each of which shall be deemed an original and all of
which together shall be deemed one and the same instrument.

     Section 6.  APPLICABLE LAW.  THIS FIRST AMENDMENT SHALL BE GOVERNED BY, AND
                 --------------
CONTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE EXCLUDING
CONFLICTS OF LAW PRINCIPLES OF SUCH JURISDICTION, EXCEPT TO THE EXTENT SUCH
MATTERS ARE MANDATORILY SUBJECT TO THE LAWS OF ANOTHER JURISDICTION PURSUANT TO
THE LAWS OF SUCH OTHER JURISDICTION.

                 [Remainder of Page Intentionally Left Blank]

                                       3
<PAGE>

     IN WITNESS WHEREOF, the Parties have executed and delivered this First
Amendment as of the date first above written.

                              OCCIDENTAL PETROCHEM PARTNER 1, INC.,
                              a Delaware corporation

                              By: /s/ Linda S. Peterson
                                 ---------------------------------------
                              Name: Linda S. Peterson
                              Title: Vice President and Secretary

                              OCCIDENTAL PETROCHEM PARTNER 2, INC.,
                              a Delaware corporation

                              By: /s/ Linda S. Peterson
                                 ---------------------------------------
                              Name: Linda S. Peterson
                              Title: Vice President and Secretary

                              OCCIDENTAL PETROCHEM PARTNER GP, INC.,
                              a Delaware corporation

                              By: /s/ Linda S. Peterson
                                 ---------------------------------------
                              Name: Linda S. Peterson
                              Title: Vice President and Assistant Secretary

                              PDG CHEMICAL INC.,
                              a Delaware corporation

                              By: /s/ Linda S. Peterson
                                 ---------------------------------------
                              Name: Linda S. Peterson
                              Title: Vice President and Assistant Secretary

                                       4
<PAGE>

                              EQUISTAR CHEMICALS, LP,
                              a Delaware limited partnership

                              By: /s/ Eugene R. Allspach
                                 ------------------------------------------
                              Name: Eugene R. Allspach
                              Title: President & Chief Operating Officer

[Signature Page to First Amendment To Occidental Asset Contribution Agreement]

                                       5EXHIBIT 10.1

Exhibit 10.1

4460 ParkAvenue

New York, NY 10022

Tel: (212) 521-1780

Fax: (212) 521-1949

Internet Address: jlo@iccchem.com

ICC INDUSTRIES INC.

JOHN L. ORAM

PRESIDENT

          October 25, 2001

Pharmaceutical Formulations Inc.

460 Plainview Avenue

Edison, New Jersey 08818

Attention:          Mr. James Ingram, President

Re:     Conversion of ICC's Preferred Shares and Rights Offering

Gentlemen:

In connection with ICC’s conversion of its 2,500,000 shares of Series A
Cumulative Redeemable Convertible Preferred Stock, this will confirm that ICC
and PFI have agreed that ICC will convert its preferred stock and unpaid
dividends at a conversion price of $.34 per share of common stock (instead of
the $.075 per share conversion price at which ICC is entitled to convert such
shares). This means that 10,441,176 shares would be issued to ICC on such
conversion, instead of the 47,333,333 shares that would have been issued at a
$.075 conversion price.

The conversion shall occur on the date of completion of the
formalities required to increase PFI’s authorized capital (i.e. immediately
following the filing of the appropriate Certificate of Amendment to PFI’s
Certificate of Incorporation, after approval at PFI’s next annual
meeting).

This will also confirm that ICC and PFI have agreed that ICC shall convert
$15,000,000 of debt owed to ICC by PFI at the same price and on the same date as
the conversion of the preferred shares, resulting in the issuance of an
additional 44,117,647 shares to ICC, for a total of 54,558,823 shares to be
issued to ICC at that time.

After the above issuances of common stock, ICC would own 74,194,718 shares (or
87.40%) of the outstanding common shares.

This will also confirm the agreement between ICC and PFI that PFI may offer the
minority shareholders the right to subscribe to a proportionate number of common
shares, also at $.34 per share, in order that their interests will not be
diluted.

If the shareholders do not approve an increase in the authorized
capital of the Company at the next shareholders’ meeting, currently
scheduled for November 28, 2001, the conversion rights under the preferred stock
and accumulated dividends will revert to the original conversion rights as
outlined in the Certificate of Designation, Preferences and Rights of Series A
Cumulative Redeemable Convertible Preferred Stock of Pharmaceutical
Formulations, Inc.; provided, however, that the conversion price shall never be
lower than the then-par value of the Company’s common stock.

If no rights offering substantially as outlined in the proxy
statement for the annual meeting takes place on or prior to December 31, 2002,
the agreements between the Company and ICC as set forth in this letter with
regard to offering stock to the minority shareholders will be null and
void.

If the Company makes a rights offering on or prior to December
31, 2002 (and no other rights offering has been made after the date of this
letter) and the price of shares that may be subscribed to by other shareholders
with regard to conversion of the preferred stock and accrued dividends and the
conversion of ICC debt is lower than $.34 per share, the conversions of
preferred stock and debt noted above shall be revised such that ICC will receive
for no additional consideration such number of additional shares at that price
per share as it would have received had it converted its preferred shares and
existing debt at that conversion price and the Company’s rights offering to
the minority shareholders shall be based on such new number of shares being
issued to ICC; provided, however, that no shares shall be issued to ICC or in
any rights offering at a price less than the par value of such
shares.

	 
	Very truly yours,

ICC INDUSTRIES INC.

/s/ John L. Oram                    

John L. Oram

JLO:leb

AGREED:

PHARMACEUTICAL FORMULATIONS, INC.

By:     /s/  James C. Ingram                    

          James C. Ingram

          President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]